Introduction
Spondyloarthropathies [SpA] include a group of chronic inflammatory rheumatic conditions, which are characterized by inflammation of vertebrae, peripheral joints and periarticular tissues. Etiology is unknown but genetical tendency, infectious agents and environmental factors may play a role. Undifferentiated spondyloarthropathy [USpA] is a SpA subtype also characterized by inflammatory back pain and arthritis, and it does not conform to the criteria for Ankylosing spondylitis [AS], Reiter's syndrome, psoriatic arthritis or inflammatory bowel disease arthritis [1] .
Bath ankylosing spondylitis functional index [BASFI] and disease activity index [BASDAI] are often used to evaluate the USpA condition [2] . A number of previous studies [3] - [5] indicating that BASDAI could reflect the disease activity of both USpA and AS patients. ASAS group has advised the fatigue question of the Bath Ankylosing Spondylitis Disease Activity Index [BASDAI] as the most appropriate measure of fatigue in daily practice [6] .
The multidimensional assessment of fatigue scale [MAF] was appropriate to measure self-reported fatigue in adults with rheumatoid arthritis and other chronic conditions. The MAF is a self-administered questionnaire developed to measure five dimensions of self-reported fatigue: degree, severity, distress, impact on activities of daily living and timing [7] .
To our knowledge, there is no study regarding the multidimensional nature of fatigue and health-related quality of life [HRQOL] in patients with USpA. This study aims to evaluate the fatigue in Turkish patients with USpA, and its relationships with disease-specific variables, spinal mobility measures and healthy-related quality of life [HRQOL].
Materials and Methods
Eighty patients who were admitted to our outpatient clinic and fulfilling European Spondyloarthropathy Study Group [ESSG] criteria for USpA [1] ; and forty sedanter healthy volunteers were with similar demographic characteristics included in this study. All patients were over 18 years old [20 -65 years] . Written consents were also obtained from each patient and healthy control. Patients with malignancies, fibromyalgia syndrome or other systemic inflammatory rheumatic diseases were not included in the study. Demographic variables were collected in all cases.
Assessment criteria in this study: 1. Duration of morning stiffness (minute), presence of night pain, history of peripheral arthritis, symptom duration (since the diagnosis of USpA), and metrological measures (finger-floor distance, lumbar schober, occiputwall distance, and chest expansion) were measured.
2. Visual analog scale [VAS] was used to determine the pain intensity related to USpA [0 -10], 0 = no pain and 10 = severe pain imaginable.
3. The Bath Ankylosing Spondylitis Disease Activity Index translated into Turkish dialect and validated was used to assess self-reported disease activity [8] . Three levels of disease activity were defined: a score <4 meant mildly active disease, a score of 4 -6 indicated moderate disease activity, and a score of >6 defined severe disease activity [9] . The question related to fatigue in the BASDAI was evaluated separately. Patients who have BASDAI score of >5 are accepted to have fatigue. 
Statistics
Data were analyzed using SPSS version 17.0 for Windows. Descriptive statistics were used to describe demographic characteristics. Comparative analyses of demographic characteristics between patients and controls were computed using either the Man-Whitney U test or the Chi squared test depending on the levels of measurement. Mean group scores were compared using Man-Whitney U test between patients and controls and BASDAI fatigue groups. Spearman correlation tests were used to determine the relationships between the variables. The level of significance was set at p < 0.05. The mean total score of MAF was 29.97 ± 12.11 in patients. Patients with USpA had significantly higher scores in MAF total and all MAF subgroup scales than controls. All SF-36 subgroups scores were also found to be significantly lower in patients. [p < 0.000] ( Table 1) . The demographical and clinical data were shown in Table 2 .
Results

Eighty patients with
It was observed that 60% of USpA patients had fatigue [BASDAI fatigue > 5] . Sixty percent [48] of the patients were included in the Fatigue + group, and forty percent [32] of the patients were in the Fatigue − group. atigue + group scored significantly different from the Fatigue − group with respect to each subscales of the MAF, all disease-specific variables [duration of morning stiffness, history of night pain, chest expansion, BASDAI, and BASFI], and VAS-axial, VAS-peripheral and all the SF-36 subgroups scores except role emotional [RE] and role physical of SF 36. In Fatigue − group, presence of HLA B27 was significantly higher than Fatigue + group [p > 0.05] ( Table 3) .
Clinical and demographic data and disability scores in patients with USpA and correlations with MAF scores were summarized in Table 4 . In patients, the MAF total score was found to be significantly correlated with duration of morning stiffness, BASDAI, BASFI, BASDAI fatigue, and VAS-axial [p < 0.05 and r < −0.5 or p < 0.05 and r > 0.5]. No correlation was observed between MAF total score and age, BMI, education level, disease duration, metrological measures, ESR, CRP, and medications in patients.
Correlations between dimensions of MAF and dimensions of SF-36 in patients with USpA were shown in Table 5 . In patients group, MAF total score were found to be significantly correlated with the all SF-36 subgroups scores except RE and MH subgroups scores of SF-36 [p < 0.05 and r < −0.5 or p < 0.05 and r > 0.5].
Discussion
The results of our study, which assessed fatigue multidimensionally by MAF revealed that patients with USpA had significantly higher fatigue scores when compared with healthy controls. In this study, HRQOL was evaluated by SF-36 in patients diagnosed with USpA and healthy controls. According to the results of the current study, there was a statistically significant impairment in the all subscales of the quality of life in patients. To our knowledge, this is the first study which compares fatigue and HRQOL in patients with USpA and healthy persons.
Only a few studies have been published examining determinants of fatigue in SpA, and all have focused on ankylosing spondylitis [AS] [14] . To our knowledge, there is no study which have been published examining determinants of fatigue in USpA. We assessed the properties of both the single-item question and a multidimensional assessment of fatigue questionnaire, the MAF in patients with USpA. The advantage of a single item BASDAI fatigue question is that it is very easy to complete. ASAS group has also adviced the fatigue question of the BASDAI as the most appropriate measure of fatigue in daily practice [6] . Advantage of the MAF is that it gives more details about different aspects of fatigue [14] . In our research, 60% of all patients experienced fatigue, determined as a BASDAI fatigue score of >5. Our findings suggest that fatigue is an important symptom in USpA. The other study reported that Fifty-nine percent of patients with SpA moderate to high levels of fatigue [15] . In this study, fatigue levels of the patients were found to be related to disease-specific variables [duration of morning stiffness, history of night pain, chest expansion, BASDAI, BASFI], level of axial and peripheral joint pain, the MAF and HRQOL. In present study, the MAF total score was also found to be significantly correlated with duration of morning stiffness, BASDAI, BASFI, BASDAI fatigue, and axial pain in patients. [p < 0.05]. In patients with SpA, similar relationships between fatigue and measures of self-reported disease activity, limitations in functional abilities, stiffness, and pain have also been reported by other studies [6] [16]- [18] .
Different generic and disease specific instruments are available in measuring HRQOL. In this study we used the SF-36 questionnaire that is one of the most frequently used generic tools for musculoskeletal disorders and other chronic conditions. We found that fatigue was significantly correlated with all SF-36 dimensions except RE and MH of SF 36, physical component summary [PCS] and mental component summary [MCS] . In studies investigating fatigue and health-related quality of life, an association was reported between fatigue and mental health [6] [19] . We also found a statistically significant correlation between mental component summary and fatigue. It can be thought that the association between fatigue and worse mental health may in part be explained by depression. A recent study [20] showed that nonsteroidal antiinflammatory drug therapy strongly reduced pain and functional impairment in a group of AS patients, whereas the change in fatigue level was of lower magnitude. Similarly in other studies, we found no impact of nonsteroidal anti-inflammatory drugs [NSAID] and disease-modifying antirheumatic drugs [DMARD] on fatigue degree [14] [21] . In our study, laboratory measurements like ESR and CRP were no found to be related with fatigue. Both CRP and ESR are nonspecific markers of inflammation that correlate with disease activity. Similarly recent studies [22] [23] showed no relationship between fatigue and inflammatory markers [ESR, CRP]. Thus, the relationship between fatigue and inflammatory markers is unclear, and more studies are needed to explore the issue [19] .
USpA are frequently characterized by isolated episodes of peripheral arthritis and enthesitis, axial or back pain and by a lower incidence of HLA-B27 versus AS [24] . In our present study, incidence of HLA-B27 was 37.5% in patients with USpA. In our Fatigue − group, presence of HLAB27 was significantly higher than Fatigue + group [p > 0.05]. The relationship between fatigue and presence of HLAB27 is unclear, and more studies are needed in USpA patients. 75% (24) 8.08 ± 7.09 (1 -20) 27.50 ± 32.7 (0 -120)
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